StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Myriad Genetics's ebitda for the twelve months ending Jun 30, 2026 was -$48.40M. For fiscal 2025 it was -$333.50M. The highest annual figure on record is $288.20M in fiscal 2014.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$333.50M–
FY2024Dec 31, 2024-$62.30M–
FY2023Dec 31, 2023-$195.50M–
FY2022Dec 31, 2022-$87.90M–
FY2020Jun 30, 2020-$159.70M-298.1%
FY2019Jun 30, 2019$80.60M-54.3%
FY2018Jun 30, 2018$176.30M+91.0%
FY2017Jun 30, 2017$92.30M-48.8%
FY2016Jun 30, 2016$180.20M+13.6%
FY2015Jun 30, 2015$158.60M-45.0%
FY2014Jun 30, 2014$288.20M+21.7%
FY2013Jun 30, 2013$236.90M+25.1%
FY2012Jun 30, 2012$189.39M+14.8%
FY2011Jun 30, 2011$165.00M+16.1%
FY2010Jun 30, 2010$142.16M+4.6%
FY2009Jun 30, 2009$135.91M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$26.40M–
Q1 FY2026CQ1 2026Mar 31, 2026-$18.20M–
Q4 FY2025CQ4 2025Dec 31, 2025$6.90M–
Q3 FY2025CQ3 2025Sep 30, 2025-$10.70M–
Q2 FY2025CQ2 2025Jun 30, 2025-$315.10M–
Q1 FY2025CQ1 2025Mar 31, 2025-$14.60M–
Q4 FY2024CQ4 2024Dec 31, 2024-$24.20M–
Q3 FY2024CQ3 2024Sep 30, 2024-$4.40M–
Q2 FY2024CQ2 2024Jun 30, 2024-$21.40M–
Q1 FY2024CQ1 2024Mar 31, 2024-$12.20M–
Q4 FY2023CQ4 2023Dec 31, 2023-$16.30M–
Q3 FY2023CQ3 2023Sep 30, 2023-$46.00M–
Q2 FY2023CQ2 2023Jun 30, 2023-$100.40M–
Q1 FY2023CQ1 2023Mar 31, 2023-$32.80M–
Q4 FY2022CQ4 2022Dec 31, 2022-$38.50M–
Q3 FY2022CQ3 2022Sep 30, 2022-$31.90M–
Q2 FY2022CQ2 2022Jun 30, 2022-$4.90M-152.1%
Q1 FY2022CQ1 2022Mar 31, 2022-$12.60M–
Q4 FY2020CQ2 2020Jun 30, 2020-$50.60M-495.3%
Q3 FY2020CQ1 2020Mar 31, 2020-$115.80M-578.5%
Q2 FY2020CQ4 2019Dec 31, 2019$9.40M-61.0%
Q1 FY2020CQ3 2019Sep 30, 2019-$2.70M-113.8%
Q4 FY2019CQ2 2019Jun 30, 2019$12.80M-61.1%
Q3 FY2019CQ1 2019Mar 31, 2019$24.20M-9.4%
Q2 FY2019CQ4 2018Dec 31, 2018$24.10M+24.2%
Q1 FY2019CQ3 2018Sep 30, 2018$19.50M-79.9%
Q4 FY2018CQ2 2018Jun 30, 2018$32.90M+2.2%
Q3 FY2018CQ1 2018Mar 31, 2018$26.70M+45.1%
Q2 FY2018CQ4 2017Dec 31, 2017$19.40M-35.5%
Q1 FY2018CQ3 2017Sep 30, 2017$97.20M+496.3%
Q4 FY2017CQ2 2017Jun 30, 2017$32.20M+11.0%
Q3 FY2017CQ1 2017Mar 31, 2017$18.40M-62.6%
Q2 FY2017CQ4 2016Dec 31, 2016$30.10M-42.1%
Q1 FY2017CQ3 2016Sep 30, 2016$16.30M-67.5%
Q4 FY2016CQ2 2016Jun 30, 2016$29.00M-31.3%
Q3 FY2016CQ1 2016Mar 31, 2016$49.20M+16.9%
Q2 FY2016CQ4 2015Dec 31, 2015$52.00M–
Q1 FY2016CQ3 2015Sep 30, 2015$50.10M–
Q4 FY2015CQ2 2015Jun 30, 2015$42.20M–
Q3 FY2015CQ1 2015Mar 31, 2015$42.10M–

More Myriad Genetics figures

See a number that looks wrong?